SANMINA CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SANMINA CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Oct 1, 2022 | $2.22B | May 22, 2023 |
| FY2022 | Jul 2, 2022 | $2.02B | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $1.92B | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $1.76B | May 22, 2023 |
| FY2022 | Oct 2, 2021 | $1.65B | May 22, 2023 |
| FY2022 | Jul 3, 2021 | $1.65B | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $1.68B | May 22, 2023 |
| FY2022 | Jan 2, 2021 | $1.76B | May 22, 2023 |
| FY2022 | Oct 3, 2020 | $6.95B | May 22, 2023 |
| FY2021 | Sep 28, 2019 | $8.23B | Nov 12, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $8.13B | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $7.57B | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $8.94B | Nov 13, 2025 |
| FY2024 | Oct 1, 2022 | $7.92B | Nov 27, 2024 |
| FY2023 | Oct 2, 2021 | $6.74B | Nov 16, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $6.87B | Nov 13, 2017 |
| FY2017 | Oct 1, 2016 | $6.48B | Nov 13, 2017 |
| FY2017 | Oct 3, 2015 | $6.37B | Nov 13, 2017 |
| FY2016 | Sep 27, 2014 | $6.22B | Nov 18, 2016 |
| FY2015 | Sep 28, 2013 | $5.92B | Nov 19, 2015 |
| FY2014 | Sep 29, 2012 | $6.09B | Nov 13, 2014 |
| FY2013 | Oct 1, 2011 | $6.60B | Nov 27, 2013 |
| FY2012 | Oct 2, 2010 | $6.32B | Nov 21, 2012 |
| FY2011 | Oct 3, 2009 | $5.18B | Nov 22, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $716.36M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $640.43M | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $743.21M | Nov 13, 2025 |
| FY2022 | Oct 1, 2022 | $172.23M | May 22, 2023 |
| FY2022 | Jul 2, 2022 | $162.19M | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $146.50M | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $141.30M | May 22, 2023 |
| FY2022 | Oct 2, 2021 | $130.04M | May 22, 2023 |
| FY2022 | Jul 3, 2021 | $135.07M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $120.99M | May 22, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $245.89M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $222.54M | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $309.97M | Nov 13, 2025 |
| FY2022 | Oct 1, 2022 | $58.36M | May 22, 2023 |
| FY2022 | Jul 2, 2022 | $77.22M | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $48.62M | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $56.18M | May 22, 2023 |
| FY2022 | Oct 2, 2021 | $55.93M | May 22, 2023 |
| FY2022 | Jul 3, 2021 | $116.20M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $27.87M | May 22, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $354.57M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $335.49M | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $455.66M | Nov 13, 2025 |
| FY2022 | Oct 1, 2022 | $103.35M | May 22, 2023 |
| FY2022 | Jul 2, 2022 | $91.61M | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $76.27M | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $78.24M | May 22, 2023 |
| FY2022 | Oct 2, 2021 | $65.91M | May 22, 2023 |
| FY2022 | Jul 3, 2021 | $72.74M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $42.61M | May 22, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $31.09M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $28.51M | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $26.43M | Nov 13, 2025 |
| FY2024 | Oct 1, 2022 | $21.34M | Nov 27, 2024 |
| FY2022 | Jul 2, 2022 | $5.07M | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $5.47M | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $4.78M | May 22, 2023 |
| FY2023 | Oct 2, 2021 | $20.91M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $22.56M | May 22, 2023 |
| FY2021 | Sep 28, 2019 | $27.55M | Nov 12, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $290.22M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $266.19M | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $255.07M | Nov 13, 2025 |
| FY2024 | Oct 1, 2022 | $244.57M | Nov 27, 2024 |
| FY2022 | Jul 2, 2022 | $61.51M | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $61.82M | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $61.48M | May 22, 2023 |
| FY2023 | Oct 2, 2021 | $234.54M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $240.93M | May 22, 2023 |
| FY2021 | Sep 28, 2019 | $260.03M | Nov 12, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $620.66M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $340.22M | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $235.17M | Nov 13, 2025 |
| FY2024 | Oct 1, 2022 | $330.85M | Nov 27, 2024 |
| FY2022 | Jul 2, 2022 | $248.96M | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $147.27M | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $68.30M | May 22, 2023 |
| FY2023 | Oct 2, 2021 | $338.34M | Nov 16, 2023 |
| FY2022 | Jul 3, 2021 | $246.62M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $142.90M | May 22, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $147.36M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $111.23M | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | $191.37M | Nov 13, 2025 |
| FY2024 | Oct 1, 2022 | $138.64M | Nov 27, 2024 |
| FY2023 | Oct 2, 2021 | $73.30M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $65.98M | May 22, 2023 |
| FY2021 | Sep 28, 2019 | $134.67M | Nov 12, 2021 |
| FY2020 | Sep 29, 2018 | $118.88M | Nov 13, 2020 |
| FY2019 | Sep 30, 2017 | $111.83M | Nov 8, 2019 |
| FY2018 | Oct 1, 2016 | $120.40M | Nov 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $5.86B | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $4.82B | Nov 13, 2025 |
| FY2024 | Sep 30, 2023 | $4.87B | Nov 27, 2024 |
| FY2023 | Oct 1, 2022 | $4.84B | Nov 16, 2023 |
| FY2022 | Jul 2, 2022 | $4.74B | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $4.65B | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $4.50B | May 22, 2023 |
| FY2022 | Oct 2, 2021 | $4.20B | May 22, 2023 |
| FY2022 | Jul 3, 2021 | $4.00B | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $3.77B | May 22, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Oct 1, 2022 | $1.82B | May 22, 2023 |
| FY2022 | Jul 2, 2022 | $1.77B | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $1.81B | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $1.85B | May 22, 2023 |
| FY2022 | Oct 2, 2021 | $1.85B | May 22, 2023 |
| FY2022 | Jul 3, 2021 | $1.81B | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $1.71B | May 22, 2023 |
| FY2022 | Jan 2, 2021 | $1.67B | May 22, 2023 |
| FY2022 | Oct 3, 2020 | $1.62B | May 22, 2023 |
| FY2022 | Sep 28, 2019 | $1.65B | May 22, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 28, 2019 | $28.52M | Nov 8, 2019 |
| FY2019 | Sep 29, 2018 | $28.52M | Nov 8, 2019 |
| FY2019 | Sep 30, 2017 | $59.13M | Nov 8, 2019 |
| FY2018 | Oct 1, 2016 | $59.13M | Nov 15, 2018 |
| FY2017 | Oct 3, 2015 | $26.62M | Nov 13, 2017 |
| FY2016 | Sep 27, 2014 | $25.70M | Nov 18, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | ($2.46B) | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | ($2.71B) | Nov 13, 2025 |
| FY2024 | Sep 30, 2023 | ($2.93B) | Nov 27, 2024 |
| FY2023 | Oct 1, 2022 | ($3.24B) | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | ($3.48B) | May 22, 2023 |
| FY2021 | Oct 3, 2020 | ($3.72B) | Nov 12, 2021 |
| FY2020 | Sep 28, 2019 | ($3.86B) | Nov 13, 2020 |
| FY2019 | Sep 29, 2018 | ($4.03B) | Nov 8, 2019 |
| FY2018 | Sep 30, 2017 | ($3.98B) | Nov 15, 2018 |
| FY2017 | Oct 1, 2016 | ($4.12B) | Nov 13, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | $926.27M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | $625.86M | Nov 13, 2025 |
| FY2024 | Sep 30, 2023 | $667.57M | Nov 27, 2024 |
| FY2023 | Oct 1, 2022 | $529.86M | Nov 16, 2023 |
| FY2022 | Jul 2, 2022 | $493.31M | May 22, 2023 |
| FY2022 | Apr 2, 2022 | $559.89M | May 22, 2023 |
| FY2022 | Jan 1, 2022 | $627.72M | May 22, 2023 |
| FY2022 | Oct 2, 2021 | $650.03M | May 22, 2023 |
| FY2022 | Jul 3, 2021 | $623.84M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $575.18M | May 22, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Oct 3, 2020 | $348.00M | Nov 13, 2020 |
| FY2020 | Sep 28, 2019 | $385.33M | Nov 13, 2020 |
| FY2019 | Sep 29, 2018 | $392.67M | Nov 8, 2019 |
| FY2018 | Sep 30, 2017 | $394.86M | Nov 15, 2018 |
| FY2017 | Oct 1, 2016 | $437.48M | Nov 13, 2017 |
| FY2016 | Oct 3, 2015 | $427.37M | Nov 18, 2016 |
| FY2015 | Sep 27, 2014 | $533.85M | Nov 19, 2015 |
| FY2014 | Sep 28, 2013 | $562.51M | Nov 13, 2014 |
| FY2012 | Sep 29, 2012 | $797.41M | Nov 21, 2012 |
| FY2011 | Oct 1, 2011 | $1.16B | Nov 22, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | 4 | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | 4 | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | 5 | Nov 13, 2025 |
| FY2022 | Oct 1, 2022 | 1 | May 22, 2023 |
| FY2022 | Jul 2, 2022 | 1 | May 22, 2023 |
| FY2022 | Apr 2, 2022 | 0 | May 22, 2023 |
| FY2022 | Jan 1, 2022 | 0 | May 22, 2023 |
| FY2022 | Oct 2, 2021 | 0 | May 22, 2023 |
| FY2022 | Jul 3, 2021 | 1 | May 22, 2023 |
| FY2022 | Apr 3, 2021 | 0 | May 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | 4 | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | 3 | Nov 13, 2025 |
| FY2025 | Sep 30, 2023 | 5 | Nov 13, 2025 |
| FY2022 | Oct 1, 2022 | 0 | May 22, 2023 |
| FY2022 | Jul 2, 2022 | 1 | May 22, 2023 |
| FY2022 | Apr 2, 2022 | 0 | May 22, 2023 |
| FY2022 | Jan 1, 2022 | 0 | May 22, 2023 |
| FY2022 | Oct 2, 2021 | 0 | May 22, 2023 |
| FY2022 | Jul 3, 2021 | 1 | May 22, 2023 |
| FY2022 | Apr 3, 2021 | 0 | May 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 27, 2025 | 53.40M | Nov 13, 2025 |
| FY2025 | Sep 28, 2024 | 53.92M | Nov 13, 2025 |
| FY2024 | Sep 30, 2023 | 56.83M | Nov 27, 2024 |
| FY2023 | Oct 1, 2022 | 57.39M | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | 64.31M | May 22, 2023 |
| FY2021 | Oct 3, 2020 | 65.00M | Nov 12, 2021 |
| FY2020 | Sep 28, 2019 | 69.72M | Nov 13, 2020 |
| FY2019 | Sep 29, 2018 | 67.78M | Nov 8, 2019 |
| FY2018 | Sep 30, 2017 | 71.66M | Nov 15, 2018 |
| FY2017 | Oct 1, 2016 | 73.03M | Nov 13, 2017 |